World Well being Group. Classification of Omicron (B. 1.1. 529): SARS-CoV-2 variant of concern. https://www.who.int/information/merchandise/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (2021).
Chen, J., Wang, R., Gilby, N. B. & Wei, G.-W. Omicron variant (B. 1.1. 529): infectivity, vaccine breakthrough, and antibody resistance. J. Chem. Inf. Modeling 62, 412–422 (2022).
Google Scholar
Xu, Z., Liu, Ok. & Gao, G. F. Omicron variant of SARS-CoV-2 imposes a brand new problem for the worldwide public well being. Biosaf. Well being 4, 147–149 (2022).
Google Scholar
World Well being Group. WHO coronavirus illness (COVID-19) dashboard. https://covid19.who.int/ (2020).
World Well being Group. COVID-19 Weekly Epidemiological Replace, Version 98 (WHO, 2022).
Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161–1179 (2022).
Google Scholar
McMenamin, M. E. et al. Vaccine effectiveness of 1, two, and three doses of BNT162b2 and CoronaVac towards COVID-19 in Hong Kong: a population-based observational research. Lancet Infect. Dis. 22, 1435–1443 (2022).
Google Scholar
Petráš, M. Extremely efficient naturally acquired safety towards COVID-19 persists for a minimum of 1 yr: a meta-analysis. J. Am. Med. Dir. Assoc. 22, 2263–2265 (2021).
Google Scholar
Nonaka, C. Ok. V. et al. Genomic proof of SARS-CoV-2 reinfection involving E484K spike mutation, Brazil. Emerg. Infect. Dis. 27, 1522–1524 (2021).
Google Scholar
Maier, H.E. et al. Safety related to earlier SARS-CoV-2 an infection in Nicaragua. N. Engl. J. Med. 387, 568–570 (2022).
Malato, J. et al. Threat of BA.5 an infection amongst individuals uncovered to earlier SARS-CoV-2 variants. N. Engl. J. Med. 387, 953–954 (2022).
Google Scholar
Block, J. Vaccinating individuals who have had covid-19: why doesn’t pure immunity rely within the US? BMJ 374, n2101 (2021).
Corridor, V. et al. Safety towards SARS-CoV-2 after Covid-19 vaccination and former an infection. N. Engl. J. Med. 386, 1207–1220 (2022).
Google Scholar
Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R. & Ioannidis, J. P. A. SARS-CoV-2 reinfections: overview of efficacy and length of pure and hybrid immunity. Environ. Res. 209, 112911 (2022).
Google Scholar
Altarawneh, H. N. et al. Safety towards the omicron variant from earlier SARS-CoV-2 an infection. N. Engl. J. Med. 386, 1288–1290 (2022).
Google Scholar
Dolgin, E. Is one vaccine dose sufficient when you’ve had COVID? What the science says. Nature 595, 161–162 (2021).
US Facilities for Illness Management and Prevention. Interim scientific concerns to be used of COVID-19 vaccines at the moment approved in the USA. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html (2021).
Lai, F. T. T. et al. Put up-Covid-19-vaccination opposed occasions and healthcare utilization amongst people with or with out earlier SARS-CoV-2 an infection. J. Intern. Med. 291, 864–869 (2022).
Google Scholar
Cowling, B. J. et al. Affect evaluation of non-pharmaceutical interventions towards coronavirus illness 2019 and influenza in Hong Kong: an observational research. Lancet Public Well being 5, e279–e288 (2020).
Google Scholar
Burki, T. Hong Kong’s fifth COVID-19 wave-the worst but. Lancet Infect. Dis. 22, 455–456 (2022).
Google Scholar
Centre for Well being Safety of the Division of Well being Hong Kong SAR. Archives of newest scenario of instances of COVID-19. https://www.chp.gov.hk/en/options/102997.html (2022).
Centre for Well being Safety of the Division of Well being Hong Kong SAR. Newest scenario of COVID-19 (as of 30 June 2022). https://www.chp.gov.hk/recordsdata/pdf/local_situation_covid19_en.pdf (2022).
Centre for Well being Safety of the Division of Well being Hong Kong SAR. Factsheet on COVID-19 vaccination for individuals with prior COVID-19 an infection. https://www.covidvaccine.gov.hk/pdf/factsheet_priorCOVID19infection_ENG.pdf (2022).
Ebinger, J. E. et al. Antibody responses to the BNT162b2 mRNA vaccine in people beforehand contaminated with SARS-CoV-2. Nat. Med. 27, 981–984 (2021).
Google Scholar
Krammer, F. et al. Antibody responses in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1372–1374 (2021).
Google Scholar
Goldberg, Y. et al. Safety and waning of pure and hybrid immunity to SARS-CoV-2. N. Engl. J. Med. 386, 2201–2212 (2022).
Google Scholar
Nordström, P., Ballin, M. & Nordström, A. Threat of SARS-CoV-2 reinfection and COVID-19 hospitalisation in people with pure and hybrid immunity: a retrospective, complete inhabitants cohort research in Sweden. Lancet Infect. Dis. 22, 781–790 (2022).
Google Scholar
Abu-Raddad, L. J. et al. Affiliation of prior SARS-CoV-2 an infection with danger of breakthrough an infection following mRNA vaccination in Qatar. Jama 326, 1930–1939 (2021).
Google Scholar
Epsi, N.J. et al. Understanding “hybrid immunity”: comparability and predictors of humoral immune responses to extreme acute respiratory syndrome coronavirus 2 an infection (SARS-CoV-2) and coronavirus illness 2019 (COVID-19) vaccines. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciac392 (2022).
Anderson, M. et al. SARS-CoV-2 antibody responses in infection-naive or beforehand contaminated people after 1 and a couple of doses of the BNT162b2 vaccine. JAMA Netw. Open 4, e2119741 (2021).
Google Scholar
Gelanew, T. et al. A single dose of ChAdOx1 nCoV-19 vaccine elicits excessive antibody responses in people with prior SARS-CoV-2 an infection akin to that of two-dose-vaccinated, SARS-CoV-2-infection-naïve People: a longitudinal research in Ethiopian well being employees. Vaccines 10, 859 (2022).
Google Scholar
Hwang, J.-Y. et al. Humoral and mobile responses to COVID-19 vaccines in SARS-CoV-2 infection-naïve and -recovered Korean people. Vaccines 10, 332 (2022).
Google Scholar
Shenai, M.B., Rahme, R. & Noorchashm, H. Equivalency of safety from pure immunity in COVID-19 recovered versus absolutely vaccinated individuals: a scientific evaluate and pooled evaluation. Cureus 13, e19102 (2021).
Eythorsson, E., Runolfsdottir, H. L., Ingvarsson, R. F., Sigurdsson, M. I. & Palsson, R. Fee of SARS-CoV-2 reinfection throughout an omicron wave in Iceland. JAMA Netw. Open 5, e2225320 (2022).
Google Scholar
Gazit, S. et al. Extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: a retrospective cohort research. Clin. Infect. Dis. 75, e545–e551 (2022).
Google Scholar
Bettini, E. & Locci, M. SARS-CoV-2 mRNA vaccines: immunological mechanism and past. Vaccines 9, 147 (2021).
Sette, A. & Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell 184, 861–880 (2021).
Google Scholar
Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and length of immunity: a longitudinal research. Lancet Microbe 2, e240–e249 (2021).
Google Scholar
Melenotte, C. et al. Immune responses throughout COVID-19 an infection. Oncoimmunology 9, 1807836 (2020).
Google Scholar
Glatman-Freedman, A., Bromberg, M., Dichtiar, R., Hershkovitz, Y. & Keinan-Boker, L. The BNT162b2 vaccine effectiveness towards new COVID-19 instances and issues of breakthrough instances: a nation-wide retrospective longitudinal a number of cohort evaluation utilizing individualised information. eBioMedicine 72, 103574 (2021).
Google Scholar
Lopez Bernal, J. et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 associated signs, hospital admissions, and mortality in older adults in England: check unfavorable case-control research. BMJ 373, n1088 (2021).
Google Scholar
Wan, E.Y.F. et al. Vaccine effectiveness of BNT162b2 and CoronaVac towards SARS-CoV-2 Omicron BA.2 an infection, hospitalisation, extreme issues, heart problems and mortality in sufferers with diabetes mellitus: a case management research. J. Infect. 85, e140–e144 (2022).
Lau, H. et al. Evaluating the huge underreporting and undertesting of COVID-19 instances in a number of international epicenters. Pulmonology 27, 110–115 (2021).
Google Scholar
Berec, L. et al. Safety supplied by vaccination, booster doses and former an infection towards covid-19 an infection, hospitalisation or dying over time in Czechia. PLoS ONE 17, e0270801 (2022).
Google Scholar
Ferrara, P. et al. Time-varying impact of hybrid immunity on the chance of breakthrough an infection after booster dose of mRNA COVID-19 vaccine: the MOSAICO research. Vaccines 10, 1353 (2022).
Lai, F. T. T. et al. Multimorbidity and opposed occasions of particular curiosity related to Covid-19 vaccines in Hong Kong. Nat. Commun. 13, 411 (2022).
Google Scholar
Lai, F. T. T. et al. Carditis after COVID-19 vaccination with a messenger RNA vaccine and an inactivated virus vaccine: a case–management research. Ann. Intern. Med. 175, 362–370 (2022).
Google Scholar
Lai, F. T. T. et al. Opposed occasions of particular curiosity following the usage of BNT162b2 in adolescents: a population-based retrospective cohort research. Emerg. Microbes Infect. 11, 885–893 (2022).
Google Scholar
Polack, F. P. et al. Security and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Google Scholar
